interleukin-2 + programmed cell death protein 1 inhibitor

Interleukin-2 + PD-1 refers to a combination therapeutic regimen consisting of the cytokine interleukin-2 (IL-2) and a checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor. In clinical development, such as Grit Biotechnology's GT201 program, this combination is utilized to enhance the activity and persistence of autologous tumor-infiltrating lymphocytes (TILs) in patients with advanced solid tumors. IL-2 provides essential growth signals to T-cells, while the PD-1 inhibitor prevents tumor-mediated T-cell exhaustion by blocking inhibitory signaling. This dual approach aims to overcome the immunosuppressive tumor microenvironment and improve the efficacy of adoptive cell therapies or endogenous immune responses.

Other names

IL-2 + PD-1 inhibitorinterleukin-2 + anti-PD-1IL-2 + PD-1interleukin-2 + PD-1